International Edition
World Markets FX Policy

Tuesday, 6 October 2026

Private Trade News

Global markets, trading & world business — for professional traders

Trading

Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial

Private Trade News venue-risk note (2026-10-06): Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial (RTTNews) - Kairos Pharma, Ltd. (KAPA), a clinical-stage… Primary source: original at Nasdaq Market Structure (nasdaq.com).

· Nasdaq Market Structure

Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial

(RTTNews) - Kairos Pharma, Ltd. (KAPA), a clinical-stage biopharmaceutical company, announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer

Read at source

Read also